Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive Co: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Colgate-Palmolive common stock (0%). The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
Colgate-Palmolive Company is asking stockholders to vote at its 2026 virtual Annual Meeting on May 8, 2026. Investors are being asked to elect ten director nominees, ratify PricewaterhouseCoopers as independent auditor, and approve an advisory vote on executive compensation, while the Board recommends voting against two stockholder proposals.
The proxy describes a refreshed 2030 strategy focused on organic sales growth, earnings and free cash flow, supported by brand reach, science-based innovation, omni-channel demand generation, data and AI capabilities, and an inclusive culture. It highlights strong governance practices, a largely independent and diverse Board, robust risk and cybersecurity oversight, and a pay-for-performance executive compensation program where most senior pay is variable and equity-based. Sustainability, climate targets and human capital development are presented as integral to long-term value creation.
Colgate-Palmolive Company director Christopher S. Boerner has filed an initial Form 3 insider ownership report. The summarized data shows no reported buy or sell transactions, no derivative exercises, and no gift, tax, or restructuring entries in this filing excerpt.
Colgate-Palmolive Company is changing how it reports its business segments as part of its Strategic Growth and Productivity Program. Effective for the quarter ending March 31, 2026, the former Europe and Africa/Eurasia segments (excluding Russia and Belarus) and the Skin Health business will be combined into a new Europe, Middle East and Africa reportable segment. Russia and Belarus will now be included in the Asia Pacific reportable segment.
The company states this realignment does not affect its historical consolidated results of operations, financial position or cash flows. For consistency, it has recast historical geographic segment information. In the recast data, total net sales were $20,382 million with operating profit of $3,306 million for the year ended December 31, 2025, and total net sales were $19,457 million with operating profit of $3,984 million for the year ended December 31, 2023.
Colgate-Palmolive Company reported board changes centered on leadership expertise. On March 12, 2026, the board elected Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company, as a director effective March 15, 2026. He will be compensated under Colgate-Palmolive’s existing non-employee director compensation program as described in its March 26, 2025 proxy statement.
On the same date, director Steven A. Cahillane informed the board that he will not stand for reelection at the Annual Meeting of Stockholders scheduled for May 8, 2026, due to the demands of his new role as Chief Executive Officer of The Kraft Heinz Company.
Colgate-Palmolive notifies removal of its 0.500% Notes due 2026 from listing and registration on the New York Stock Exchange LLC. The Exchange and the issuer each certified compliance with the applicable 17 CFR 240.12d2-2 procedures for voluntary withdrawal.
Colgate-Palmolive Chief Growth Officer John Hazlin reported equity compensation activity involving company common stock. On February 23, 2026, he acquired 12,803 shares through the vesting of performance-based restricted stock units granted under the incentive compensation plan. On the same date, 6,117 shares were disposed of at $97.10 per share to cover tax withholding related to that vesting. After these transactions, Hazlin directly owned 24,422 shares and indirectly held 5,452 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary Jennifer Daniels reported equity compensation activity in Common Stock. She acquired 25,742 shares through the vesting of previously granted performance-based restricted stock units that were earned under the company’s incentive compensation plan and settled in stock. To cover tax liabilities from this vesting, 12,351 shares were withheld at a price of $97.10 per share. After these transactions, she directly held 89,844 shares and indirectly held 1,837 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive EVP and Controller Malcolm Gregory reported equity award activity in company stock. He acquired 6,268 shares of Common Stock at a price of $0.0000 per share through the vesting of previously granted performance-based restricted stock units under the issuer's incentive compensation plan, which are settled solely in shares.
On the same date, 2,260 shares of Common Stock were disposed of at $97.1000 per share to cover tax liabilities associated with the PBRSU vesting. Following these transactions, he directly held 15,898 shares of Common Stock. In addition, 8,554 shares are held indirectly through the issuer's 401(k) plan trustee.